Direct acting oral anticoagulant: Bench to bedside.

Area of Science:

• Pharmacology
• Cardiovascular Medicine
• Hematology

Background:

• Vitamin K antagonists (VKAs) are effective oral anticoagulants but require constant monitoring due to narrow therapeutic windows and interactions.
• Genetic variability and drug/food interactions lead to unpredictable anticoagulant effects with VKAs.

Purpose of the Study:

• To review direct-acting oral anticoagulants (DOACs) for stroke prevention in nonvalvular atrial fibrillation and venous thromboembolism treatment/prevention.
• To compare the clinical uses and limitations of DOACs versus VKAs.

Main Methods:

• Review of current literature on DOACs, including direct thrombin inhibitors and factor Xa inhibitors.
• Analysis of safety and efficacy profiles, clinical applications, and limitations of DOACs.

Main Results:

• DOACs (dabigatran, rivaroxaban, apixaban, edoxaban) demonstrate better safety and efficacy than VKAs.
• DOACs have limitations including gastrointestinal bleeding risk (except apixaban) and thrombotic risk upon cessation, but antidotes improve safety.

Conclusions:

• DOACs represent a significant advancement in oral anticoagulation therapy.
• Understanding the clinical uses and limitations of DOACs is crucial for optimizing patient care.